{'52WeekChange': 1.7643981,
 'SandP52WeekChange': None,
 'address1': '300 The American Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 41.18,
 'askSize': 1100,
 'averageDailyVolume10Day': 1812350,
 'averageVolume': 3703423,
 'averageVolume10days': 1812350,
 'beta': 3.349019,
 'beta3Year': None,
 'bid': 41.21,
 'bidSize': 1100,
 'bookValue': 0.87,
 'category': None,
 'circulatingSupply': None,
 'city': 'Morris Plains',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 42.0299,
 'dayLow': 40.23,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -27.799,
 'enterpriseToRevenue': 30454,
 'enterpriseValue': 8983929856,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '973 605 8282',
 'fiftyDayAverage': 37.295143,
 'fiftyTwoWeekHigh': 44.48,
 'fiftyTwoWeekLow': 8.8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 204552064,
 'forwardEps': -0.9,
 'forwardPE': -45.78889,
 'fromCurrency': None,
 'fullTimeEmployees': 366,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00137,
 'heldPercentInstitutions': 0.81313,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 488419200,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/immunomedics.com',
 'longBusinessSummary': 'Immunomedics, Inc., a clinical-stage '
                        'biopharmaceutical company, develops monoclonal '
                        'antibody-based products for the targeted treatment of '
                        'cancer. Its advanced antibody-drug conjugates are '
                        'sacituzumab govitecan and labetuzumab govitecan, '
                        'which are in advanced trials for various solid tumors '
                        'and metastatic colorectal cancer, respectively. The '
                        'company focuses on commercializing sacituzumab '
                        'govitecan as a third-line therapy for patients with '
                        'metastatic triple-negative breast cancer in the '
                        'United States. It also develops IMMU-140, a humanized '
                        'antibody directed against an immune response target. '
                        'Its other product candidates include products for the '
                        'treatment of cancer and autoimmune diseases, '
                        'including epratuzumab, an anti-CD22 antibody; '
                        'veltuzumab, an anti-CD20 antibody; milatuzumab, an '
                        'anti-CD74 antibody; and IMMU-114, a humanized '
                        'anti-HLA-DR antibody. The company has clinical '
                        'collaboration with AstraZeneca, MedImmune, and Roche; '
                        'collaboration agreement with The Bayer Group; '
                        'clinical and preclinical collaborations with academic '
                        'cancer institutions; and research collaboration with '
                        'the Memorial Sloan Kettering Cancer Center. It also '
                        'has a partnership agreement with the Samsung '
                        'BioLogics Co., Ltd. to manufacture hRS7, an '
                        'Immunomedics proprietary humanized antibody; and a '
                        'collaboration and license agreement with pH Pharma '
                        'Co. Ltd. for the development and commercialization of '
                        'multiple novel antibody-drug conjugates in oncology. '
                        'The company was founded in 1982 and is headquartered '
                        'in Morris Plains, New Jersey.',
 'longName': 'Immunomedics, Inc.',
 'market': 'us_market',
 'marketCap': 9515388928,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_279328',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -362900000,
 'nextFiscalYearEnd': 1640908800,
 'open': 41.26,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.46,
 'phone': '973 605 8200',
 'previousClose': 42.24,
 'priceHint': 2,
 'priceToBook': 47.367813,
 'priceToSalesTrailing12Months': 32255.557,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 42.0299,
 'regularMarketDayLow': 40.23,
 'regularMarketOpen': 41.26,
 'regularMarketPreviousClose': 42.24,
 'regularMarketPrice': 41.26,
 'regularMarketVolume': 3215541,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 230900000,
 'sharesPercentSharesOut': 0.1145,
 'sharesShort': 26440305,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 28924512,
 'shortName': 'Immunomedics, Inc.',
 'shortPercentOfFloat': 0.1282,
 'shortRatio': 6.12,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'IMMU',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.822,
 'twoHundredDayAverage': 25.362158,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '2f709bcc-d532-3fde-b3fb-238fd607894c',
 'volume': 3215541,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.immunomedics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '07950'}